HORIZON program provides treatment recommendations for patients with moderate to severe psoriasis (Part 2)

HORIZON program provides recommendations for psoriasis patients with specific joint involvement. Dr. Wayne Gulliver, Chair and Medical Director of NewLab Clinical Research in St, John’s, speaks about the efficacy of IL-17 inhibitors and TNFs for treatment of psoriatic arthritis.

Discovery of new RNA molecule could be key for early detection of skin cancer

The discovery of a new RNA molecule could lead to earlier detection of squamous cell carcinoma in the future, according to a new study. The study, published in the American Journal of Pathology (Feb. 2020; 190(2):503-517), found that the molecule, named PRECSIT, is integral in determining how squamous cell carcinoma grows and spreads.

Repurposed topical cream may be key to curbing mosquito-borne diseases

Applied within an hour of mosquito bite, the topical cream imiquimod may reduce the chance of transmission of viral diseases such as Zika and dengue, according to a new study. Researchers of the study, published in Science Translational Medicine (Jan 22, 2020; 12(527)), found that the skin cream, when applied immediately after a mosquito bite, helps to activate immune system response.

Active ingredients in sunscreens may absorbed into skin at higher levels than previously thought

Absorption of the active ingredients in four commercially available sunscreens resulted in plasma concentrations that exceed the FDA safety threshold in participants in a new study. Researchers of the study, published in JAMA (Jan 21, 2020; 323(3):256-267) stressed that these findings do not suggest that individuals should stop using sunscreen.

Combination of Two Immunotherapies Brings Advanced Melanoma Survival Rate to 50% for First Time

By combining two existing therapies, researchers at the Royal Marsden NHS Foundation Trust in London have found that they have been able to stop or even reverse the progression of advanced melanoma in half of patients. The two therapies, ipilmumab and nivolumab, were tested on patients over the course of five years. The findings were published online ahead of print in the New England Journal of Medicine (Sept. 28, 2019).